Five things for pharma marketers to know: Friday, March 23, 2018

Share this content:

GlaxoSmithKline has pulled its bid for Pfizer's consumer health business. The deadline to put in an official offer for the consumer business, worth as much as $20 billion, was this week. It's unclear if other buyers are interested. Pfizer is considering other options including a spin-off, sale or other type of transaction, or retaining the business. (CNBC)


The government funding bill passed by the Senate includes more money for the FDA. The FDA's discretionary budget under this spending bill is $135 million more than last year. FDA efforts getting extra funding are the Oncology Center of Excellence and an initiative addressing the opioid crisis. The spending bill is headed to the president's desk. (Endpoints News)


Pfizer's anti-smoking drug Chantix failed a study in teens and pre-teens. The research studied individuals ages 12 to 16 in the U.S. and 12 to 17 in Europe, but did not meet its primary goal of a four-week continuous abstinence rate. (Reuters)


Pennsylvania's attorney general has partnered with Rite Aid and the Pittsburgh Penguins to fight prescription drug abuse. The program will target high schoolers and teach them about the dangers of abusing opioids. The Rite Aid Foundation also plans to introduce the program in eastern Pennsylvania, Ohio, Washington, and Oregon. (CNBC)


There's hope for a birth control pill for men, but with side effects. Researchers at the University of Washington found a formulation that appears to be safe, but it comes with similar side effects as birth control for women, including weight gain. (Washington Post)


Share this content:
Scroll down to see the next article